May 27, 1998 |
Six million healthy Americans with ordinary cholesterol levels might benefit from taking cholesterol-lowering drugs, researchers said. Healthy men and women taking lovastatin, sold as Mevacor, reduced their risk of serious heart trouble 37%, according to a five-year study in the Journal of the American Medical Assn. Currently, national guidelines recommend cholesterol-lowering drugs only for people with high cholesterol.
CALIFORNIA | LOCAL
May 15, 1989 |
A team of Stanford University researchers said last week that evidence regarding the value of reducing cholesterol is "incomplete," adding that low cholesterol may actually be associated with a higher death rate in the elderly. Dr. Benjamin Littenberg, a clinical scholar, and two other doctors said they reviewed more than 100 published papers about cholesterol screening. They concluded that the value of such tests is questionable for adults with no symptoms of heart disease. Their recommendations, published in the April 15 volume of the Annals of Internal Medicine, fly in the face of recent campaigns by the National Institutes of Health and the American Medical Assn.
June 23, 1997 |
Drugs that lower cholesterol to help prevent heart attacks also may thwart the most common type of stroke, researchers said. Drugs such as Zocor and Pravachol reduced the risk of stroke by an estimated 27%, an analysis of 12 studies involving 19,518 patients with high cholesterol found. Researchers say the drugs, known as reductase inhibitors, may avert strokes by cleaning arteries, preventing their deterioration or forestalling heart attacks.
September 9, 2003 |
Widely used cholesterol-lowering drugs do not appear to raise the risk of suicide and might even reduce depression, according to researchers trying to clarify conflicting earlier studies. Some previous studies appeared to connect older cholesterol-lowering drugs to an increased risk of unintentional injury, aggression and suicide. Other recent research suggested no such link.
CALIFORNIA | LOCAL
December 9, 1988 |
An experimental hormone that has shown promise in boosting the immune system of patients with AIDS and blood diseases also has an unexpected ability to lower cholesterol in the bloodstream, according to UCLA Medical Center researchers. The finding, being reported in Thursday's issue of the Journal of the American Medical Assn., may stimulate research to develop new cholesterol-lowering drugs, according to Dr. Stephen D.
September 2, 1987 |
The Food and Drug Administration on Tuesday authorized the sale of a cholesterol-lowering drug that could help millions of people reduce their risk of heart attacks and strokes. The prescription drug, taken as a tablet once or twice a day, is called lovastatin and will be available in two or three weeks under the brand name Mevacor. It will be marketed by Merck Sharp & Dohme of West Point, Pa. Dr. Michael Brown and Dr.
August 13, 2003 |
The Food and Drug Administration approved the cholesterol-lowering drug called Crestor after long debate about the risk of side effects. Made by AstraZeneca Pharmaceuticals, Crestor, a statin, comes with a warning about taking higher-than-recommended doses, which have contributed to rare cases of a potentially fatal, muscle-destroying condition called rhabdomyolysis.
July 28, 1989 |
For the first time, researchers have identified a biochemical mechanism by which high cholesterol levels can help trigger colorectal and pancreatic cancers, two of the five most deadly tumors among U.S. cancer victims. Epidemiological studies had previously linked diets high in meat and other fatty foods, as well as high cholesterol levels, to colorectal cancer, but researchers had virtually no idea what role cholesterol played in tumor formation.
June 1, 1992 |
A growing body of evidence suggests that diets and drugs that lower blood cholesterol levels may indirectly raise the risk of certain types of violent death by producing personality changes--inducing anger, irritability, aggressiveness and increased risk-taking. The studies have set off competing waves of concern and skepticism in the medical community.
August 21, 1996 |
A little-known form of "bad" cholesterol that doctors cannot yet measure reliably may cause early heart disease just as often as its better-known cousins, a study suggests. The lesser-known culprit, called lipoprotein(a), may lurk in dangerously high levels in the blood of people whose other cholesterol levels appear normal on routine tests, researchers say.